YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine
| YSDelisted Stock | 0.48 0.03 5.88% |
Slightly above 62% of YS Biopharma's investor base is looking to short. The analysis of current outlook of investing in YS Biopharma Co, suggests that many traders are alarmed regarding YS Biopharma's prospects. YS Biopharma's investing sentiment can be driven by a variety of factors including economic data, YS Biopharma's earnings reports, geopolitical events, and overall market trends.
YS Biopharma |
YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine
Read at kalkinemedia.com
 |
YS Biopharma Fundamental Analysis
We analyze YS Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of YS Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of YS Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Earnings Per Share
Earnings Per Share Comparative Analysis
YS Biopharma is currently under evaluation in earnings per share category among its peers. Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
YS Biopharma Co, Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with YS Biopharma stock to make a market-neutral strategy. Peer analysis of YS Biopharma could also be used in its relative valuation, which is a method of valuing YS Biopharma by comparing valuation metrics with similar companies.
Peers
YS Biopharma Related Equities
| CDIO | Cardio Diagnostics | 9.26 | ||||
| ZURA | Zura Bio | 0.72 | ||||
| QNRX | Quoin Pharmaceuticals | 0.14 | ||||
| ZVSA | ZyVersa Therapeutics | 0.00 | ||||
| CNSP | Cns Pharmaceuticals | 0.91 | ||||
| VRAX | Virax Biolabs | 1.63 | ||||
| BDRX | Biodexa Pharmaceticals | 2.90 | ||||
| SONN | Sonnet Biotherapeutics | 5.71 | ||||
| REVB | Revelation Biosciences | 5.76 | ||||
| ALLR | Allarity Therapeutics | 6.42 | ||||
| IMMX | Immix Biopharma | 13.78 |
Check out Your Current Watchlist to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Other Consideration for investing in YS Biopharma Stock
If you are still planning to invest in YS Biopharma Co, check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the YS Biopharma's history and understand the potential risks before investing.
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |